SuperworthCadrenal Therapeutics EPS CVKD
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$4.92
- Latest quarter, Q2 FY26
- −$1.14
- Fiscal year 2025
- −$6.70
Cadrenal Therapeutics' earnings per share was −$4.92 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.14.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$6.70 | n/a |
| FY2024 | −$9.55 | n/a |
| FY2023 | −$10.63 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.14 | n/a | −$4.92 | |
| Q1 FY26 | −$1.04 | n/a | −$5.65 | |
| Q4 FY25 | −$1.43 | n/a | −$6.70 | |
| Q3 FY25 | −$1.31 | n/a | −$8.84 | |
| Q2 FY25 | −$1.87 | n/a | −$9.71 | |
| Q1 FY25 | −$2.09 | n/a | −$10.08 | |
| Q4 FY24 | −$3.57 | n/a | −$9.55 | |
| Q3 FY24 | −$2.18 | n/a | −$7.05 | |
| Q2 FY24 | −$2.24 | n/a | −$5.88 | |
| Q1 FY24 | −$1.56 | n/a | −$4.99 | |
| Q4 FY23 | −$1.07 | n/a | −$10.63 | |
| Q3 FY23 | −$1.01 | n/a | n/a |
Against its peers
Companies in Healthcare nearest Cadrenal Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CVKDCadrenal Therapeutics | −$4.92 | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| MSGMMotorsport Games | $0.43 | +187% a year |
| ATCHAtlasClear | $0.01 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Cadrenal Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.